Regs Or No Regs, FDA Will Seek Adherence To ClinicalTrials.gov Mandates
This article was originally published in The Gray Sheet
Executive Summary
Manufacturer confusion over ClinicalTrials.gov trial registration and reporting requirements is no excuse for failing to make a good-faith attempt at compliance, FDA and NIH officials say
You may also be interested in...
Data In The Raw: Yale Doc Hopes Medtronic Infuse Effort Will Spark Data Transparency Model
The Yale physician behind Medtronic’s recent decision to hand over all of its raw data on the embattled Infuse spinal bone graft for independent analyses and ultimate release to the broader research community sees the development as not only a smart decision for Medtronic but also as a major step forward in creating a model for the device and drug industries.
Data In The Raw: Yale Doc Hopes Medtronic Infuse Effort Will Spark Data Transparency Model
The Yale physician behind Medtronic’s recent decision to hand over all of its raw data on the embattled Infuse spinal bone graft for independent analyses and ultimate release to the broader research community sees the development as not only a smart decision for Medtronic but also as a major step forward in creating a model for the device and drug industries.
Submitters Still Confused On Adverse Event Reporting To ClinicalTrials.gov
Device and drug firms that submit details about their clinical trials to ClinicalTrials.gov are still having problems reporting adverse events data, Deborah Zarin, the Web site's director, told the FDA Risk Communication Advisory Committee Nov. 12